The San Francisco drug developer, jarred four years ago by partner Pfizer Inc.’s sudden decision to kill Nektar’s lead product, expects to start a Phase II trial by the middle part of 2012 of the first new pain-fighting opioid in several years.
Friday, January 20, 2012
Nektar high on development of new opioid
The San Francisco drug developer, jarred four years ago by partner Pfizer Inc.’s sudden decision to kill Nektar’s lead product, expects to start a Phase II trial by the middle part of 2012 of the first new pain-fighting opioid in several years.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment